Editorial
Origin of Anti-DNA Autoantibodies in SLE Antibodies against DNA were first described more than 25 years ago in sera of patients with systemic lupus erythematosus (SLE)L and since then research has mainly concentrated on the investigation of the pathogenic role as well as the origin of anti-DNA autoantibodies. These autoantibodies still represent the . best serological marker for SLE.
The development of anti-DNA hybridomas from lupusprone mice as well as from SLE patients and the analysis of their immunoglobulin variable genes provided important t information on induction mechanisms. Initially a paradoxical finding seemed to be that normal individuals can express anti-DNA antibodies with similar specificity as SLE patients. Now it has become clear that these so called natural autoantibodies are usually of the IgM isotype, have low affinity to DNA, particularly to double stranded DNA, are polyreactive and bear germhne encoded gene sequences. In the mouse at least a part of these natural antibodies are produced by a subset of B lymphocytes, CD5+ B cells or LyI~B cells. A possible role of these natural antibodies in immunity seems to be within first line defence mechanisms against invading microorganisms. They also might be of importance in antigen presentation to T cells as shown for rheumatoid factor-secreting B cells2 and recently in a transgenic mouse model3 . B lymphocytes expressing these natural antibodies make up a large proportion of the fetal repertoire, thereby contributing to natural immunity in the developing immune systee and participating in shaping the adult B cell repertoireli In contrast, pathogenic anti-DNA antibodies in lupus patients and lupus-prone mice are typically of the IgG isotype and have a high affinity to _dsDNA and are hardly detectable in the sera of healthy individuals. Detailed studies of hybridomas reflecting these pathogenic anti-DNA antibodies established from various lupus-prone inbred mice 6,7 as well as from SLE patients 8,9 revealed that the IgG anti-DNA response showed all the characteristics of in vivo selection of autoantigen reactive B lymphocytes. Thus, they show somatic mutations in their variable regions that are accumulated in the complementarity determining regions (curs) contacting the antigen. Within single autoimmune individuals, a typical oligoclonality of the anti-DNA reactive B cells was observed. Arginines or asparagines have been frequently observed in the CDR regions of high affinity anti-DNA-antibodies. These amino acids are.particularly important for protein binding to DNA and could be generated by non-template-encoded processes in the CDR3 regions, by atypical reading frame usage of the D elements, frameshifts in the VK-JK joining or by somatic mutations. All these data suggest that antigen has selected these B cell clones in uivo and that the antigen probably represents native DNA or DNA/protein complexes.
These observations indicate that the pathogenic anti-DNA antibodies resemble antibodies generated against conventional antigens in a secondary immune response.
Several questions emerge from these findings. The structure and the origin of the antigen triggering and sustaining this response is of interest. DNA might be released in significant amounts during cell death. However, native dsDNA per se is not immunogenic. In cells dying by apoptosis, fragmentation of DNA into oligonucleosomal pieces is taking place and these nuclcc~~s~mes might be a candidate antigen for both T and B lymphocytes (as discussed later). One also could think of viral protein/DNA complexes as a potential immunogen that starts the autoimmune response.
The similarity of the anti-DNA response in SLE and B cell responses involved in secondary immune responses against antigenic challenge raises the question of the role of T cells, especially T helper cells, in driving the anti-DNA antibodies. It is well known that only T cell-dependent immune responses show the characteristics of affinity maturation, memory formation and isotype switch. The classic experiments of Wofsy and Seaman'O indeed showed that continuous anti-CD4 therapy can modulate anti-DNA autoantibody production and prevent the development of lupus nephritis in three different lupus-prone mice strains. However, as demonstrated more recently by Wofsy's group, a substantial depletion of CD4 cells in addition to thymectomy early in life with a consequently life-long reduction of CD4+ cells to < 10% of the initial number did not alter significantly anti-DNA titers later in life of ~TZ:~~N~~ Fi ~rnic~~l. These findings should have significant implication for anti-CD4 therapy trials that are under way in lupus patients. T cell clones from lupus-prone mice and SLE patients able to induce B cells to produce and-DNA antibodies in vitro have been described 12-14 . The specificity of the interaction, however, remains to a large extent a mystery. The so called 'autoreactive' T cell clones do proliferate in a MHC restricted manner to antigen-presenting cells (APC) from autoimmune as well as normal mice. Moreover, 'autoreactive' T cell clones and lines can also be established from non-autoimmune individuals. The important question of the nature of the antigenic peptide stimulating that proliferation of T cells remains unclear. On the other hand, the specifity of help for anti-DNA antibody production is at least questionable as prior activation in vivo of anti-DNA reactive B cells or simply a high precursor frequency of anti-DNA reactive B cells in autoimmune individuals might result in an in vitro anti-D~t~ production as caused by the secretion of certain lymphokines or non-antigen specific help by the T cells, In this context the lymphc~kyne spectrum secreted by the respective T cell clone might be crucial for anti-DNA production as it has been shown recently that all T helper clones from autoimmune mice which are able to provide help for anti-DNA production produce IL-4 but no IFN-gamma and therefore belong to the TH2 phenotype 14 A recent report by Datta and his colleagues might shed some light on the antigen and the specificity of those T cells that could provide help specifically to anti-DNA reactive B cells. In autoimmune mice T cells with reactivity to nucleosomes were describes 15. Interestingly, all of the T cell clones described showed responses only when nucleosomes were processed and presented by antigen-presenting cells but not when the protein portion, namely histones, were used as antigen alone. These findings suggest a cognate interaction of histone-specific T cells with DNA-specific B cells similar to the classical hapten-carrier concept with the requirement for a specific processing of the antigen by lymphocytes. The existence of T cell clones with a similar specificity as in the murine SLE model, however, has not been shown in SLE patients.
The most common immunological abnormality shared by all animal models for SLE as well as SLE patients is a pronounced B cell hyperactivity. It has been shown that this so called polyclonal B cell activation procedes and predicts the development of the autoimmune disease in lupus-prone mice 16 . Two recent investigations highlight the role of CD4' T cells for the B cell hyperactivity and the production of IgM as well as IgG anti-DNA autoantibodies. By the transfer of long-term in vitro cultivated pre-B cells from (NZB X NZW) F1 mice into SCID mice Reiniuger et al. 17 reported the development of many features of an autoimune disease including IgG anti-DNA antibodies in the absence of T lymphocytes as well as other donor-derived hematopoetic cells. These studies clearly showed that major diseasedetermining genes are expressed in the B lineage. Other cell lineages, especially T lymphocytes, might only modulate the progression of the disease. A similar conclusion was reached by lVlerino et c~l.ls, treating (NZB X NnV) F1 mice with anti-CD4 antibodies from birth up to 2 months of age. The characteristic IgM polyclonal B cell activation was not influenced at all by the complete depletion of CD4+ T cells early in life. In contrast, ~I)4~ T cells appear to be responsible for the immunological abnormality in MRL-lpr! lpr mice as total IgM serum levels and IgM anti-DNA titers were nornialized by anti-CD4' treatment, The described experiments show that different mechanisms could influence the development of the B cell hyperactivity occurring in SLE which might be an important first step towards production of high affinity, pathogenic IgG anti-DNA antibodies. ether genetically determined defects of different cell lineages are responsible for disease manifestations in subgroups of SLE patients is completely unclear. The clinical heterogeneity of systemic lupus and inconsistent association of HLA and other markers with the disease argue in favor of a .multifactorial etiology'9. It is likely that similar subtypes of lupus as precedent in the NZB~1V~;W and 1VIRL-lprl~~ar models will eventually be defined among SLE patients. For the development of specific therapeutic concepts the knowledge of the gentic defects expressed in the different lineages in human lupus would be of crucial importance.
